Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2020-07-19
Target enrollment:
Participant gender:
Summary
This clinical trial studies sorafenib tosylate in treating patients with liver cancer that
cannot be removed by surgery. Sorafenib tosylate may block some of the enzymes needed for
tumor cell growth. Blocking these enzymes may also help the immune system work better.
Granzyme B is a biomarker that can be used to measure how well the immune system is working.
A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a
sign of a normal or abnormal process, or of a condition or disease. Studying granzyme B
levels in patients receiving sorafenib tosylate may help doctors learn more about the effects
of sorafenib tosylate on the immune system and may help to predict how well sorafenib
tosylate will work in treating patients with liver cancer.